Hookipa pharma inc. (HOOK)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Revenue from collaboration and licensing

3,696

3,618

2,038

4,051

2,235

-

1,900

649

-

Operating expenses:
Research and development

11,526

11,179

11,025

13,929

10,179

4,615

6,170

6,211

4,969

General and administrative

4,629

5,664

4,589

3,751

2,711

2,669

1,282

1,413

1,480

Total operating expenses

16,155

-

15,614

-

12,890

-

7,452

-

-

Total operating expenses

-

-

-

17,680

-

-

-

7,624

6,449

Loss from operations

-12,459

-13,225

-13,576

-13,629

-10,655

-2,204

-5,552

-6,975

-6,449

Other income (expense):
Grant income

1,472

2,743

1,258

1,544

1,192

395

1,762

1,384

2,071

Interest income

312

447

565

511

64

-

-

0

-

Interest expense

227

227

227

210

213

200

194

191

193

Other income and expenses, net

-24

-91

604

-195

283

114

33

-36

22

Total other income, net

1,533

2,872

2,200

1,650

1,326

309

1,601

1,157

1,900

Net loss before tax

-10,926

-10,353

-11,376

-11,979

-9,329

-1,895

-3,951

-5,818

-4,549

Income tax expense

0

-109

9

100

0

45

2

1

-24

Net loss

-10,926

-10,244

-11,385

-12,079

-9,329

-1,892

-3,953

-5,819

-4,573

Other comprehensive loss:
Foreign currency translation gain (loss), net of tax

-93

266

-763

300

-736

-636

-243

-3,018

1,539

Comprehensive loss

-11,019

-9,978

-12,148

-11,779

-10,065

-2,528

-4,196

-8,837

-3,034

Net loss per share—basic and diluted

-0.43

7.94

-0.45

-0.63

-9.27

-2.02

-4.34

-6.38

-5.02

Weighted average common shares outstanding — basic and diluted

25,630

25,783

25,408

19,240

1,006

922

911

911

911